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Background: Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher
frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with
increased hepatic steatosis. Previous studies of the PNPLA3 I148M sequence variant in HCV infected individuals
have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis. To evaluate
the impact of PNPLA3 I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3
infected patients.
Methods: Three hundred and eighty-two treatment naïve HCV genotype 2 or 3 infected patients were included in
a phase III, open label, randomized, multicenter, investigator-initiated trial (the NORDynamIC study), in which
pretreatment liver biopsies were mandatory. PNPLA3I148M genotyping was performed in a total of 359
Caucasian patients.
Results: In HCV genotype 2 infected patients carrying the PNPLA3 148M allele, there was significantly increased
insulin resistance (P = 0.023) and lower viral load (P = 0.005) at baseline as well as the first seven days of antiviral
treatment. These results were not observed in HCV genotype 3 infected patients.
Conclusions: Our results suggest a possible association between the PNPLA3 148M allele and insulin resistance as
well as baseline viral load in HCV genotype 2, but not in genotype 3.
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Chronic hepatitis C virus (HCV) infection is a major
cause of cirrhosis and liver failure [1]. Hepatic steatosis
is twice as common in HCV infected patients as in the
normal population [2] and it is associated with fibrosis
and cirrhosis development [3,4]. Metabolic host factors,
mainly obesity, insulin resistance and type 2 diabetes,
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reproduction in any medium, provided the ordevelopment in non–genotype 3 infected individuals,
whereas HCV genotype 3-associated hepatic steatosis
appears to mainly result from a direct viral action [4-6].
A single genetic variant, I148M, entailing a change
from isoleucine (I) to methionine (M) at position 148 in
the human patatin-like phospholipase domain contain-
ing 3 gene (PNPLA3, Adiponutrin) on chromosome 22
has been widely associated with increased hepatic steato-
sis [7-11]. Recently, in a murine model, PNPLA3 was
found to be involved in the hepatic metabolism of trigly-
cerides and in the regulation of systemic glucose homeo-
stasis [12]. Even if previous reports failed to find an
association with insulin resistance assessed by euglyce-
mic hyperinsulinemic clamp or surrogates in humans
[8,13-15], a recent study reported that PNPLA3 I148Mal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glycaemic population from Taiwan [16]. Furthermore,
the PNPLA3 148M allele genetic variant was found to be
associated with lower serum triglyceride and higher fast-
ing glucose levels in individuals with gallstones [17]. In
the setting of HCV infection, PNPLA3 I148M sequence
variant has been extensively associated with steatosis, fi-
brosis progression, cirrhosis and hepatocellular carcinoma
[18-21]. So far, no association has been reported between
the PNPLA3 I148M variant and insulin resistance or tri-
glyceride levels in individuals with HCV infection [18,20].
The aim of the present study was to examine the im-
pact of PNPLA3 I148M variant on metabolic traits and
treatment response in a well phenotyped HCV genotype
2 and 3 cohort, within the framework of the NORDy-
namIC treatment trial [22].
Methods
Patients
Three hundred and eighty-two treatment naïve HCV
genotype 2 or 3 infected patients were included in a phase
III, open label, randomized, multicenter, investigator-
initiated trial (the NORDynamIC study) conducted at 31
centers in Denmark, Finland, Norway, and Sweden.
Details regarding demographics and clinical characteristics
have been previously reported [22]. Briefly, all patients
were adults with compensated liver disease, had detectable
HCV RNA, and were seronegative for hepatitis B surface
antigen and for antibodies to human immune deficiency
virus. A liver biopsy consistent with chronic hepatitis C
within 24 months prior to inclusion was also required. At
study entry, patients were randomized to either 12 or
24 weeks of treatment with 180 μg of peg-interferon α-2a
once weekly and 800 mg/day ribavirin. After excluding all
non-Caucasians as well as two patients positive for both
HCV genotypes 2 and 3, a total of 359 patients were
examined. Alcohol consumption was measured as stand-
ard drink units (12 g of pure alcohol) per day [23].
PCR PNPLA3 genotyping, rs738409
The variation at rs738409 was determined by amplification
on an ABI7300 (Applied Biosystems) using rs738409_F,
GTGCCTGTCGTGTACTGAACCA as forward primer,
rs738409_R, AGCGCGGAGTGCAATTCA as reverse
primer, and Taqman MGB (minor groove binding)
probes (rs738409-pC, FAM-CTGCTTCATCCCCTTC-
MGB, rs738409-pG, VIC-GGAAGGAGGGATAAGGC
CACT-MGB) for allelic discrimination.
Serum metabolic parameters
Baseline fasting glucose (mmol/L) was measured at indi-
vidual sites on freshly drawn serum, whereas fasting
serum insulin was analyzed on frozen samples at the
central laboratory (mU/L, Architect Insulin, Abbott,Abbott Park, IL). Diabetes mellitus was defined as fast-
ing serum glucose ≥ 7.0 mmol/L. Insulin resistance was
assessed by using the homeostatic model assessment in-
sulin for resistance (HOMA-IR) index. The gold stand-
ard for insulin resistance assessment is the euglycemic
hyperinsulinemic clamp technique [24]. However, this
method is demanding and time-consuming and there-
fore is not commonly used in genetic and epidemiologic
studies. The HOMA-IR is a well known and widely used
surrogate index to quantify insulin resistance that is
highly correlated with clamp estimations [25,26].
HOMA-IR was calculated using the formula: (Glucose
mmol/L × Insulin mU/L)/22.5 [27].
Histological assessment
Fibrosis and necroinflammatory activity were assessed
according to the Ishak protocol by two experienced
observers in a dual observer consensus fashion as
described [22,28]. Specifically, presence of fibrosis was
defined as Ishak stage ≥1, and cirrhosis as Ishak stage 5–
6. Steatosis was graded as follows: absent (grade 0), mild
(less than 30 % of hepatocytes involved, grade 1), moder-
ate (30-70 % of hepatocytes involved, grade 2) or severe
(>70 % of hepatocytes involved, grade 3), although in the
present study reported as absent or present (grade 1–3).
HCV RNA quantification
HCV RNA was determined by RT-PCR of plasma using
Cobas AmpliPrep/COBAS TaqMan HCV Test (Roche
Diagnostics, Branchburg, NJ), which quantifies HCV
RNA with a limit of detection of 15 IU/mL. HCV RNA
quantification was performed on days 0, 3, 7, 8, 29, and
on weeks 8, 12, and 24 (for those receiving 24 weeks of
therapy), and 24 weeks after completion of therapy. All
samples were frozen (−70 °C), and subsequently analyzed
at a central laboratory.
Statistical methods
Continuous variables were presented as median and the
range between the 25th and 75th percentile (interquar-
tile range). Categorical variable distributions were com-
pared using either the χ2 test or the Fisher’s exact test.
Continuous variables were analyzed with linear regres-
sion, when necessary after logarithmic transformation in
order to create a normal distribution. Metabolic para-
meters were adjusted for age, gender and body mass
index (BMI). Both additive (add) and recessive (rec) in-
heritance models were tested. Binary logistic regression
analysis was used to calculate allelic odds ratio and 95 %
confidence interval. Frequency distribution of genetic
variants was evaluated according to the Hardy Weinberg
equilibrium. All statistical analyses were performed using
the IBM SPSS statistics version 19 (IBM Corporation,
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<0.05 was considered statistically significant.
Ethical considerations
The Regional Ethics Review Board in Gothenburg
approved the study. All patients signed informed con-
sent. The study is registered at the NIH trial registry
(ClinicalTrials.gov Identifier: NCT00143000).
Results
PNPLA3 I148M genotype
A total of 359 individuals were analyzed for the PNPLA3
I148M genotype (II, IM or MM). Among these, 103 were
infected with HCV genotype 2 and 256 with genotype 3.
The distribution of the PNPLA3 I148M genotype was in
Hardy Weinberg equilibrium (P=0.691 for genotype 2
and P= 0.468 for genotype 3, Additional file 1: Table S1).
The PNPLA3 I148M genotype frequency in our study co-
hort (Additional file 1: Table S1) was consistent with pre-
viously reported frequencies for Northern Europeans [29].
Study group characteristics stratified by HCV genotype 2
or HCV genotype 3 infection are described in Table 1.
Individuals with HCV genotype 2 infection were on aver-
age nine years older, they had lower alanine transferase
(ALT) levels and lower degree of steatosis compared toTable 1 Baseline characteristics stratified by HCV
genotype
HCV genotype
2 n= 103
HCV genotype
3 n= 256
P value
Male gender, n (%) 62 (60) 154 (60) 0.920
Age, years 49 (41–54) 40 (32–48) <0.001
BMI, kg/m2 25a (23–27) 25b (23–28) 0.290
ALT, U/l 74a (44–144) 108a (66–175) <0.001
Total cholesterol, mmol/L 4.6c (4.1-5.4) 3.9d (3.3-4.6) <0.001
Triglycerides, mmol/L 0.9c (0.7-1.3) 0.9d (0.7-1.4) 0.748
Glucose, mmol/L 4.9d (4.6-5.4) 4.9e (4.5-5.4) 0.507
Insulin, mIU/L 12f (6–24) 12e (7–26) 0.458
HOMA-IR, U 2.5g (1.3-6.0) 2.7h (1.6-5.9) 0.088
Baseline HCV RNA,
log10 IU/mL
6.5 (5.8-6.8) 6.1 (5.4-6.7) 0.025
Steatosis1, n (%) 49c (50) 171i (73) <0.001
Cirrhosis2, n (%) 14c (14) 29i (12) 0.807
Diabetes mellitus, n (%) 4d (4) 7e (3) 0.823
Categorical traits, expressed as number (n) and relative proportion (%), have
been compared by χ2 test. Continuous traits are expressed as median
(interquartile range) and have been analyzed using a linear regression model.
For additional information on statistical analyses, see methods.
1Steatosis was defined as histological grade > 0. 2Cirrhosis was defined as Ishak
stage 5–6.
Missing data: an = 1, bn = 8, cn = 4, dn = 6, en = 15, fn = 7, gn = 13, hn = 27,in = 23.
Abbreviations: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine
transferase; HOMA-IR, homeostasis model assessment for insulin resistance; II,
individuals with two 148I alleles; MM, individuals with two 148 M alleles; IM,
heterozygotes.individuals with HCV genotype 3 infection. They also had
higher total cholesterol and HCV RNA at baseline com-
pared to the HCV genotype 3 group (Table 1).
Clinical and biochemical profile
PNPLA3 148M allele carriers were found to have
increased insulin resistance in HCV genotype 2 infected
patients (Padd= 0.023, Prec= 0.005; Table 2 and Figure 1
A). No association with insulin resistance and the
PNPLA3 148M allele was found in individuals with
HCV genotype 3 (Table 3 and Figure 1 B). Results were
virtually identical after excluding individuals with dia-
betes mellitus (HCV genotype 2 HOMA-IR (U): II 1.8
[1.1-4.2], IM 3.0 [1.4-6.7], MM 9.0 [4.8-21.7]; Padd=
0.003, Prec= 0.002; HCV genotype 3 HOMA-IR (U): II
2.6 [1.5-5.8], IM 2.6 [1.6-4.8], MM 2.5 [1.5-8.4]; Padd=
0.811, Prec= 0.973). No significant association of trigly-
ceride levels with PNPLA3 I148M genotypes was found
in either HCV genotype 2 or 3 patients (Tables 2 and 3).
In HCV genotype 2 individuals, the PNPLA3 148M allele
was found to be associated with higher ALT levels only if
analyzed under a recessive inheritance model (Prec=
0.045, Table 2). Carriage of the PNPLA3 148M allele was
not associated with age, gender, BMI or total cholesterol
in either HCV genotype group (Tables 2 and 3).
Viral kinetics
Among the HCV genotype 2 infected individuals, the
PNPLA3 148M allele was associated with lower viral
load at baseline (Padd= 0.005, Prec= 0.073, Table 2), on
day 3 (Padd= 0.014 Prec= 0.130) and on day 7 (Padd=
0.003, Prec= 0.036; Figure 2A). In contrast, HCV geno-
type 3 patients with the PNPLA3 148M allele genotype
had higher baseline viral load (Padd= 0.030, Prec= 0.100,
Table 3). No further associations between the PNPLA3
genotype and viral load during treatment (Figure 2B),
first or second phase decline in HCV RNA, or final
treatment outcome (sustained viral response rate in the
HCV genotype 2 group was 66, 70 and 100 % and in the
HCV genotype 3 group 67, 74 and 67 %, respectively in
the II, IM and MM groups respectively), were observed.
Liver histology
A trend, although non-significant, towards a higher preva-
lence of steatosis was observed in PNPLA3 148M allele
carriers in both HCV genotype 2 and 3 subjects (Tables 2
and 3). PNPLA3 148M allele was found associated with
hepatic steatosis increased risk, although non-significant,
in HCV genotype 2 (allelic Odds Ratio, O.R. = 2.3, 95 %
Confidence Interval C.I. = 0.9-5.5, Padd=0.053, Prec=
0.154, after adjustment for age, gender and BMI) and 3
(allelic O.R. = 1.7, 95 %C.I. = 0.9-3.4, Padd=0.096, Prec=
0.991, after adjustment for age, gender and BMI) subjects.
No association between the prevalence of cirrhosis and
Table 2 Baseline characteristics according to PNPLA3 I148M sequence variant in HCV genotype 2 patients
II IM MM P value P value
n= 56 n=43 n=4 additive recessive
Male gender, n (%) 33 (59) 27 (63) 2 (50) 0.830 0.999
Age, years 50 (42–56) 48 (37–54) 51 (36–53) 0.370 0.887
BMI, kg/m2 25 (23–27) 25a (22–27) 23 (21–33) 0.773 0.981
ALT, U/l 73a (44–150) 72 (39–137) 147 (88–455) 0.406 0.045
Total cholesterol, mmol/L 4.8b (4.1-5.5) 4.6a (4.2-5.1) 4.2 (3.9-5.8) 0.283 0.756
Triglycerides, mmol/L 1.0b (0.8-1.3) 0.9a (0.7-1.3) 0.7 (0.4-1.3) 0.094 0.065
Glucose, mmol/L 4.9d (4.6-5.1) 5.0e (4.5-5.4) 4.5 (4.2-5.6) 0.502 0.724
Insulin, mIU/L 10d (5–23) 13c (7–29) 48 (24–86) 0.027 0.001
HOMA-IR, U 1.9e (1.1-4.5) 2.9f (1.4-6.7) 9.0 (4.8-21.7) 0.023 0.005
Baseline HCV RNA, log10 IU/mL 6.5 (6.0-6.9) 6.4 (5.3-6.8) 5.3 (4.7-6.4) 0.005 0.073
Steatosis1, n (%) 23b (43) 23a (55) 3 (75) 0.327 0.362
Cirrhosis2, n (%) 7b (13) 6a (14) 1 (25) 0.669 0.462
Diabetes mellitus, n (%) 3d (6) 1e (3) 0 (0) 0.694 0.998
Categorical traits, expressed as number (n) and relative proportion (%), have been compared by Fisher exact test. Continuous traits are expressed as median
(interquartile range) and have been analyzed using a linear regression model. For additional information on statistical analyses, see methods.
1Steatosis was defined as histological grade > 0. 2Cirrhosis was defined as Ishak stage 5–6.
Missing data: an = 1, bn = 3, cn = 5, dn = 2, en = 4, fn = 9.
Abbreviations: PNPLA3, patatin-like phospholipase domain-containing 3; HCV, hepatitis C virus; BMI, body mass index; ALT, alanine transferase; HOMA-IR,
homeostasis model assessment for insulin resistance; II, individuals with two 148I alleles; MM, individuals with two 148 M alleles; IM, heterozygotes.
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genotype 2 or 3 infected subjects (Tables 2 and 3).
Discussion
The main finding of the present study is the association
between the PNPLA3 148M allele and increased insulin
resistance and lower baseline viral load among HCV
genotype 2 infected patients. PNPLA3 I148M is the most
widely replicated genetic variant associated with
increased hepatic steatosis [7-11,30]. Moreover, PNPLA3
148M allele carriers with HCV infection have been
reported to have increased prevalence of steatosis, fibro-
sis, cirrhosis and hepatocellular carcinoma [18-21].Figure 1 Homeostasis model assessment for insulin resistance (HOMA
stratified by the PNPLA3 I148M genotype. P values were calculated usin
HOMA-IR values and adjusted for age, gender and BMI.Recent studies on the PNPLA3 148M allele and glucose
metabolism suggest a possible involvement of this allele
as a genetic determinant [16,17].
In this study an association between increased insulin
resistance and the PNPLA3 148M allele was observed.
This association was specifically present in HCV geno-
type 2 and it was not observed among HCV genotype 3
infected patients. Steatosis is tightly associated with in-
sulin resistance [31,32]; however, the causal nature of
this association remains to be fully elucidated. Insulin
resistance has been commonly thought to be a risk fac-
tor for liver fat accumulation [33,34]. Nevertheless, new
evidence suggests that hepatic steatosis might be-IR) in HCV genotype 2 (A) and genotype 3 (B) infected patients,
g linear regression after logarithmic transformation of
Table 3 Baseline characteristics according to PNPLA3 I148M sequence variant in HCV genotype 3 patients
II IM MM P value P value
n= 159 n= 91 n=6 additive recessive
Male gender, n (%) 97 (61) 52 (57) 5 (83) 0.466 0.407
Age, years 39 (31–47) 41 (35–48) 42 (29–46) 0.128 0.653
BMI, kg/m2 26a (23–29) 25a (23–28) 26 (22–28) 0.232 0.644
ALT, U/l 108 (68–175) 106d (62–181) 69 (61–109) 0.398 0.248
Total cholesterol, mmol/L 4.0e (3.3-4.7) 3.8a (3.2-4.5) 3.7 (3.1-5.7) 0.909 0.452
Triglycerides, mmol/L 0.9e (0.7-1.3) 0.9a (0.7-1.4) 0.8 (0.6-1.1) 0.336 0.256
Glucose, mmol/L 4.9c (4.5-5.6) 4.9f (4.6-5.3) 4.8 (4.6-5.4) 0.147 0.882
Insulin, mIU/L 13g (7–26) 12h (7–25) 12 (6–39) 0.800 0.785
HOMA-IR, U 2.7i (1.5-6.1) 2.6j (1.6-4.7) 2.5 (1.5-8.4) 0.882 0.941
Baseline HCV RNA, log10 IU/mL 6.0 (5.3-6.7) 6.2 (5.6-6.7) 6.8 (6.1-7.1) 0.030 0.100
Steatosis1, n (%) 99k (68) 68c (82) 4d (80) 0.068 0.989
Cirrhosis3, n (%) 17k (12) 11c (13) 1d (20) 0.636 0.489
Diabetes mellitus, n (%) 6c (4) 1f (1) 0 (0) 0.520 0.996
Categorical traits, expressed as number (n) and relative proportion (%), have been compared by Fisher exact test. Continuous traits are expressed as median
(interquartile range) and have been analyzed using a linear regression model. For additional information on statistical analyses, see methods.
1Steatosis was defined as histological grade > 0. 2Cirrhosis was defined as Ishak stage 5–6.
Missing data: an = 4, bn = 18, cn = 8, dn = 1, en = 2, fn = 7, gn = 9, hn = 6, in = 16, jn = 11, kn = 14.
Abbreviations: PNPLA3, patatin-like phospholipase domain-containing 3; HCV, hepatitis C virus; BMI, body mass index; ALT, alanine transferase; HOMA-IR,
homeostasis model assessment for insulin resistance; II, individuals with two 148I alleles; MM, individuals with two 148 M alleles; IM, heterozygotes.
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lin resistance [16,32,35]. The association of PNPLA3
148M allele with HOMA-IR in HCV infected subjects
supports the hypothesis that insulin resistance may be
interpreted as a consequence rather than a cause of hep-
atic steatosis. To date the role of the PNPLA3 I148M
variant on insulin resistance has been controversial, hav-
ing some previous studies failed to find this association
[8,13-15]; however our result is consistent with a recent
study performed in normoglycaemic subjects from Tai-
wan [16] that reports 148M allele carriers having higher
HOMA-IR levels. Further studies in larger cohorts are
warranted to confirm this result.Figure 2 HCV viral load according to the PNPLA3 I148M genotype in
start of treatment (day 0) through treatment week 12 (day 84). Viral lo
calculated for the difference in viral load across PNPLA3 I148M genotypes aInterestingly, we found that lower baseline viral load
was associated with the PNPLA3 148M allele in HCV
genotype 2 but not in HCV genotype 3 infected patients.
This finding is novel [20], although difficult to interpret.
HCV has been shown to exploit lipoprotein assembly
and export pathways for the release of virions from
infected hepatocytes [36-38]. Since PNPLA3 148M allele has
been reported to influence lipid accumulation in the
liver [39], it is possible to hypothesize that PNPLA3
148M allele may impair both viral and lipoprotein release
from infected hepatocytes resulting in lower baseline
plasma viral load in HCV genotype 2 infection. In the
presence of HCV genotype 3 infection, however, theHCV genotype 2 (A) and genotype 3 (B) infected patients from
ad is expressed as mean log10 value at each time point. P values were
t each time point using linear regression.
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production appears to be overridden by viral factors.
An important limitation of the present study is the
relative small sample size of the HCV genotype 2
infected patients, as well as relative lower rate of
PNPLA3 148M allele carriage in Northern Europeans as
compared to previous reports from Southern Europe. In
fact, even though steatosis has been widely reported to
be associated with PNPLA3 148M allele [7,18-20], only a
non-significant trend towards higher prevalence of stea-
tosis was observed among PNPLA3 148M allele carriers
in both HCV genotypes in the present study. However,
in the analysis adjusted for confounders, the increased
risk of steatosis reached marginal significance in geno-
type 2 but not 3 infected individuals, despite the three-
fold larger sample size of the latter group. This is in line
with previous data showing an association between the
PNPLA3 I148M genotype and steatosis in the HCV
genotype 2 but not in the HCV genotype 3 infected sub-
jects [18,19]. Similarly, the relative small sample size of
HCV genotype 2 infected patients in the present study
may have contributed to the lack of association of the
PNPLA3 148M allele with therapeutic outcome despite
its effect on baseline viral load and insulin resistance. It
is important to bear in mind that given the small sample
size our results should be carefully interpreted due to
the possibility of both false positive and negative associa-
tions. Therefore, this should be considered as a prelim-
inary report and the results need to be confirmed in
larger patient cohorts.
Conclusions
Our results suggest an association between the PNPLA3
148M allele and insulin resistance as well as viral load in
HCV genotype 2, but not genotype 3 infected indivi-
duals. Additional further genetic studies are required to
elucidate the relationship between HCV infection, meta-
bolic traits and PNPLA3 I148M genetic variant.
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